Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole Genome Microarray comparison of two Interferon Beta 1a Pharmaceutical Preparations

ABSTRACT: We have investigated the in vitro pharmacodynamic genomic effects of interferon beta 1a treatment on a whole genome microarray assay on lymphocytes from Multiple Sclerosis patients comparing the similarity between two biological products manufactured by two pharmaceutical companies. Keywords: Drug pharmacogenomics

ORGANISM(S): Homo sapiens

PROVIDER: GSE6692 | GEO | 2008/06/30

SECONDARY ACCESSION(S): PRJNA99075

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Pharmaceutical sludge

Project description:Pharmaceutical sludge Metagenome

| PRJNA509337 | ENA

Characterizing circulating pharmacodynamic biomarkers of IFNβ-1a biologics [low]

Project description:The current project is designed to evaluate the utility of proteomics in identifying pharmacodynamic (PD) biomarkers for biosimilarity assessment. This is an extension of the data submitted in GSE207945 which profiled longitudinal plasma samples from healthy subjects treated with single therapeutic doses/high doses of IFNβ-1a (30 μg) or Pegylated IFNβ-1a (125 μg) or placebo, to identify candidate PD biomarkers for the two biologics (n=248 for IFNβ-1a and N=528 for pegIFNβ-1a). The current project is a continuation study profiling longitudinal plasma samples from healthy subjects treated with a low dose of IFNβ-1a (7.5 μg) and pegIFNβ-1a (31.25 μg). In the current study, we reproduced the previous PD biomarker candidate responses at an intermediate/lower dose IFNβ-1a (15 μg) and pegIFNβ-1a (62.5 μg), and further characterized their PD response using characteristics such as significant area under the effect curve, dose-response, temporal profile and return to baseline, variability and sensitivity of the biomarker with sensitive doses on the steep portion of the dose-response curve and mechanism of action using the three tested dose-groups (high, intermediate and low) in the study.

2026-06-23 | GSE300489 | GEO

Characterizing circulating pharmacodynamic biomarkers of IFNβ-1a biologics [low]

Project description:Characterizing circulating pharmacodynamic biomarkers of IFNβ-1a biologics [low]

| PRJNA1281052 | ENA

Characterizing circulating pharmacodynamic biomarkers of IFNβ-1a biologics [inter]

Project description:Characterizing circulating pharmacodynamic biomarkers of IFNβ-1a biologics [inter]

| PRJNA1281053 | ENA

Characterizing circulating pharmacodynamic biomarkers of IFNβ-1a biologics [inter]

Project description:The current project is designed to evaluate the utility of proteomics in identifying pharmacodynamic (PD) biomarkers for biosimilarity assessment. This is an extension of the data submitted in GSE207945 which profiled longitudinal plasma samples from healthy subjects treated with single therapeutic doses/high doses of IFNβ-1a (30 μg) or Pegylated IFNβ-1a (125 μg) or placebo, to identify candidate PD biomarkers for the two biologics (n=248 for IFNβ-1a and N=528 for pegIFNβ-1a). The current project is a continuation study profiling longitudinal plasma samples from healthy subjects treated with an intermediate/lower dose of IFNβ-1a (15 μg) and pegIFNβ-1a (62.5 μg). Here, we reproduced the previous PD biomarker candidate responses at a lower dose, and further characterized their PD response using characteristics such as significant area under the effect curve, dose-response, temporal profile and return to baseline, variability and sensitivity of the biomarker with sensitive doses on the steep portion of the dose-response curve and mechanism of action using all three tested dose groups (high, intermediate and low).

2026-06-23 | GSE300488 | GEO

Expression data of multiple sclerosis patients receiving intramuscular Interferon-beta-1a therapy [U133 A and B]

Project description:The purpose of this study was to characterize the transcriptional effects induced by intramuscular IFN-beta-1a treatment (Avonex, 30 µg once weekly) in patients with relapsing-remitting form of multiple sclerosis (MS). By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells from 24 MS patients within the first four weeks of IFN-beta administration. Keywords: Multiple sclerosis, Interferon, Pharmacogenomics, Affymetrix

2009-12-03 | GSE19285 | GEO

Pseudomonas sp. 1A strain:1A | isolate:1A

Project description:Pseudomonas sp. 1A strain:1A | isolate:1A Genome sequencing

| PRJNA1255296 | ENA

pharmaceutical factory16S

Project description:pharmaceutical factory16S Raw sequence reads

| PRJNA1165486 | ENA

Enterococcus mundtii 1A strain:1A

Project description:Enterococcus mundtii 1A strain:1A Genome sequencing

| PRJNA172933 | ENA

Methylobacterium sp. 1A strain:1A

Project description:Methylobacterium sp. 1A strain:1A Genome sequencing